News

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

1 February 2024

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by EuroLand Corporate.

In a study entitled L’imagerie cellulaire à la loupe, EuroLand Corporate recommends Mauna Kea shares to Buy, with a target price of €0.71, representing an increase of +56% compared with the share’s closing price on January 31, 2024 (€0.456).

This new study adds to the consensus of financial analysts who already covers the stock alongside Portzamparc and Gilbert Dupont.

Latest News

Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update